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Available online 3 September 2018Background: Inhibition of tumor necrosis factor-α (TNF) signaling is beneﬁcial in the management of ulcerative
colitis (UC), but up to one-third of patients do not have a clinical response of relevance to TNF inhibitors during
induction therapy (i.e. primary non-responders [PNRs]). Throughproduction of prostaglandins (PGs) and throm-
boxanes, cyclooxygenase-2 (COX-2) affects inﬂammation and epithelial regeneration and may in this way be
implicated in treatment resistance to TNF inhibitors.
Methods: In this study, COX-2 expression was analyzed in human intestinal biopsies and patient-derived mono-
cytes, and the downstream consequences of COX-2 activity was evaluated by assessing the inﬂuence of the
down-stream effector, PGE2, on intestinal epithelial stem cell self-renewal and differentiation using primary
human intestinal organoids (“mini-guts”).
Findings:We found that TNF stimulation induced COX-2 expression inmonocytes isolated from responders (Rs),
whereas COX-2 expression was constitutively high and non-inducible in monocytes from PNRs. Additionally,
PGE2 in combinationwith proliferative signals transformed human intestinal epithelial cells to a proinﬂammato-
ry state akin to ﬂaring UC, whereas PGE2 in combination with differentiation signals supported robust mucin in-
duction.
Interpretation:Ourwork indicates that COX-2-PGE2 signaling could be a novel target for themanagement of PNRs
to TNF inhibitors.Weadditionally demonstrate that COX-2–PGE2 signaling has dual functionsduring tissue repair
and normal lineage differentiation, explaining in part the lack of response to TNF inhibitors among PNRs.
Fund: Thisworkwas funded by grants from theNovoNordisk Foundation, the Lundbeck Foundation, the Vander-
bilt Digestive Disease Research Center, NIH Grants, Aase and Ejnar Danielsen's Foundation and the A.P. Møller
Foundation.







Ulcerative colitis (UC) and Crohn's disease (CD) are the two main
subtypes of inﬂammatory bowel disease (IBD), both with increasingenterology, Herlev Hospital,
, ole.haagen.nielsen@regionh.dk
. This is an open access article underincidence and prevalence worldwide [1]. UC is a chronic disease of
unknown etiology characterized by chronic inﬂammation of the colon
and rectum with a progressive and remitting/relapsing course [2].
Tumor necrosis factor-α (TNF) is one of the most important mediators
of the proinﬂammatory response in UC. Over the past two decades,
biologics acting by inhibiting TNF through genetically engineered
monoclonal antibody constructs (TNF inhibitors) have revolutionized
the management of UC [3]. However, up to one-third of patients fail to
achieve any clinical response of relevance within the induction phase
(i.e., 14 weeks after initiation of treatment) and are referred to as
primary non-responders (PNRs) [3,4]. It is crucial to identify thethe CC BY license (http://creativecommons.org/licenses/by/4.0/).
Research in Context
Evidence before this Study
The COX-2-PGE2 pathway has been suggested to transiently pro-
mote intestinal repair in murine studies. Moreover, the use of
COX-2 inhibitors in patients with ulcerative colitis (UC) has been
linked to an increased risk of flaring disease, although these obser-
vations have recently been questioned. Expression analysis using
material from patients suffering from UC stratified based on their
response to TNF inhibitors, suggests that COX-2 levels are elevat-
ed in the group of non-responders prior to TNF inhibitor therapy.
Added Value of this Study
Our aim was to address whether changes in the COX-2–PGE2
pathway could explain the downstream consequences of aberrant
COX-2 expression and the associated link to a relevant response
to TNF inhibitor therapy using patient derived material. We dem-
onstrate for the first time that monocytes from patients not
responding to TNF inhibitors have higher basal levels of COX-2
as compared to monocytes isolated from responders. Additional-
ly, PGE2,which is themajor downstreameffector of COX-2, exac-
erbates the expression of proinflammatory cytokines upon TNF
stimulation in human intestinal epithelial cells, thereby ameliorat-
ing the inflammatory response, and potentially it impairs the rees-
tablishment of a functional epithelial barrier.
Implications of all the Available Evidence
The present work indicates that the COX-2-PGE2 pathway should
be explored as a target for primary non-responders to TNF inhibitor
therapy as well as a prognostic biomarker for the TNF inhibitor
responsiveness.
498 Y. Li et al. / EBioMedicine 36 (2018) 497–507mechanisms governing the response to TNF inhibitors because this may
allow for early identiﬁcation of PNRs and optimization of treatment
strategies, as well as avoidance of superﬂuous treatment costs.
In addition to elevated levels of TNF in the inﬂamed colon, UC is
accompanied by colonic epithelial barrier defects [5]. Ample evidence
supports that loss of epithelial integrity contributes to prolongedmuco-
sal inﬂammation in UC, and that epithelial regeneration is crucial for the
induction of mucosal healing [2,6,7]. Due to their capability of self-
renewal and differentiation, intestinal epithelial stem cells located at
the base of intestinal crypts play a decisive role in the epithelial regen-
eration process [8]. Upon damage monocytes/macrophages are
recruited to the sites of injury where they constitute a major source of
TNF [9,10]. Differences have been observed in monocytes derived
from responders (Rs) when compared to PNRswith UC [11]. It is conse-
quently of interest to investigate whether these differences extend into
the TNF-induced inﬂammatory response thereby altering responsive-
ness to TNF inhibitors and affecting epithelial regeneration.
The cyclooxygenase (COX) enzymes consist of two isoforms, COX-1
and COX-2, which can metabolize released arachidonic acid from cell
membranes via the common precursor prostaglandin H2 (PGH2) into
different prostanoids, comprising PGE2, PGD2, PGF2α, PGI2, and throm-
boxane A2 (TxA2) [12,13]. Unlike COX-1, which is constitutively
expressed in multiple tissues, including the gastrointestinal tract, the
expression of COX-2 is typically induced by inﬂammation, such as TNF
stimulation [14,15]. Additionally, COX-2 inhibitor treatment of UC pa-
tients has for a long time been linked with an increased risk of ﬂaring
disease [16,17], although a recently published meta-analysis hasquestioned this generalization in patients with IBD [18]. Further, the
most abundant COX-derived metabolite [15], PGE2, has been shown to
be required for intestinal wound repair by promoting the differentiation
ofwound-associated epithelial cells (WAE) [19].Moreover, inhibition of
the COX-2–PGE2 pathway inmyoﬁbroblasts has been shown to increase
the susceptibility to dextran sodium sulfate (DSS)–induced experimen-
tal colitis in mice [20]. These facts combined indicate that regulation of
the COX-2–PGE2 pathway might be involved in epithelial regeneration
and could affect the clinical response of TNF inhibitor treatment in UC.
Therefore, based on the current knowledge of involvement of eicosa-
noids in a wide range of physiological and pathological processes in
the gastrointestinal tract [21], we hypothesized that responsiveness to
TNF inhibitors might be inﬂuenced by an altered regulation of prosta-
noid synthesis in the intestinal tract of patients with UC. Using
patient-derived material, we determined the TNF responsiveness of
monocytes derived from TNF inhibitor treatment responders (Rs) or
primary non-responders (PNRs), with emphasis on the COX-2 signaling
pathway.Wemeticulouslymapped the effects in vitro on cultures of in-
testinal epithelial stem cells with the aim to elucidate how the COX-2–
PGE2 pathway affects the responsiveness to anti-TNF therapy in patients
with UC.2. Materials and Methods
2.1. Study Population
Patients aged 18 to 75 years were recruited at the East Danish IBD
Centre at Herlev Hospital, University of Copenhagen, Denmark.
Following informed consent, all eligible patients had their diagnosis
of UC veriﬁed by well-established criteria [22], and their disease ac-
tivities were graded at the time of enrollment in accordance with
the Mayo score (a combined score consisting of three clinical
items: (stool frequency [0–3], rectal bleeding [0–3] and physicians'
global rating [0–3]) as well as an endoscopic score [0–3]). Thus, the
higher the total Mayo score, the more severe the UC: a score of
0–2: quiescent UC; 3–5: mild UC; 6–9: moderate UC; and 10–12: se-
vere UC [23,24]. All patients in this study were initially treated with
the TNF inhibitor, inﬂiximab used as 1st choice at the East Danish
IBD Centre administered intravenously in the dosage of 5 mg/kg
bodyweight at week 0, 2 and 6 (induction regimen) and then every
8 weeks (the latter maintenance regimen for Rs only). Thus, at
week 14 all patients were assessed as Rs or PNRs to TNF inhibitor
treatment, and a R was deﬁned as a patient with a decrease in
Mayo score of three points or more during the initial 14 weeks of
treatment [25]. In turn, a PNR was deﬁned as a patient without clin-
ically relevant improvement in Mayo score (i.e., a decline in score
from baseline of b3 despite induction therapy with a TNF inhibitor).
Except two PNRs who underwent colectomy, all the PNRs were
switched out of therapeutic class to e.g., the anti-integrin,
vedolizumab, combined with other treatments (e.g., thiopurines like
azathioprine, glucocorticoids, and 5-aminosalicylic acid [5-ASA] at
week 14). When blood samples were obtained, the Rs were placed
on maintenance TNF inhibitor therapy while PNRs received second-
line therapy (Supplemental Table S1), and the median clinical Mayo
score in both Rs and PNRs was 0 (Supplemental Table S1). Blood
samples were obtained from patients with UC, including Rs (n =
10) and PNRs (n= 10), and healthy control subjects (n= 6). Colonic
biopsies for COX-2 immunohistochemistry (IHC) were collected from
routine colonoscopies of patients with UC, including Rs (n= 10) and
PNRs (n= 10), and healthy control subjects (n= 10). Control sam-
ples were attained from patients who underwent such an examina-
tion but in whom all clinical investigations subsequently turned out
to be normal, e.g., a diagnosis of irritable bowel syndrome was
reached [26]. Information on patients included is provided in Supple-
mental Table S1.
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Blood was drawn from TNF inhibitor–experienced patients with
UC and diluted 1:1 with phosphate-buffered saline (PBS), following
isolation of peripheral blood mononuclear cells (PBMCs) by Ficoll-
Paque density gradient centrifugation (GE Healthcare, Uppsala,
Sweden). PBMCs were used for monocyte isolation of CD14+ mono-
cytes by negative immunomagnetic bead separation using the Mono-
cyte Isolation Kit II (Miltenyi Biotec, Auburn, CA, USA). After isolation,
1 × 106 monocytes per well were plated in 24-well plates (TPP,
Trasadingen, Switzerland). Then 1 ml of growth medium (RPMI-
1640 medium containing 10% human serum, 50 IU/ml penicillin, 50
μg/ml streptomycin, and 0.5 mg/ml gentamycin) was added to each
well, and the plates were incubated at 37 °C with 5% CO2 pressure.
Cells were cultured overnight and were subsequently stimulated
with 10 ng/ml of recombinant TNF (cat. no. 210-TA, R&D Systems,
Minneapolis, MN, USA) for 8 h. Unstimulated cells were used as
controls.
2.3. Crypt Isolation and Organoid Culture
Colonic biopsies were isolated from the sigmoid part of the colon
of control patients and washed thoroughly in cold Dulbecco's
phosphate-buffered saline (DPBS), and epithelial cells were isolated
after chelation using EDTA (8 mM) for 30 min on ice, followed by
vigorous shaking. After centrifuging at 125 ×g at 4 °C for 5 min, the
supernatant was removed, and 1 ml of Ad-Df+++ (Advanced
DMEM-F12 plus Glutamax, HEPES, and penicillin/streptomycin [all
obtained from Invitrogen, Carlsbad, CA, USA]) was added to resus-
pend the pellet. The number of crypts was counted under a micro-
scope. For one well on a 48-well plate, approximately 100 crypts
were suspended in 25 μl of a mixture (1:1) of Matrigel (Corning,
New York, NY, USA) and Ad-Df+++. The plate was then placed in a
37 °C incubator for 15 min to solidify the Matrigel. The organoids
were cultured in growth medium consisting of Ad-Df+++, B27 sup-
plement (Invitrogen, 50×), N2 supplement (Invitrogen, 100×), N-
acetylcysteine (Sigma-Aldrich, St. Louis, MO, USA,1 mM), A-83-01
(Tocris, Abingdon, United Kingdom, 0.5 μM), SB202190 (Selleck
Chemicals, Houston, TX, USA, 10 μM), nicotinamide (Sigma-Aldrich,
10mM), recombinant epidermal growth factor (EGF; Thermo Fisher,
Waltham, MA, USA, 50 ng/ml), Noggin (Peprotech, Rocky Hill, NJ,
USA, 100 ng/ml), and R-spondin 1–conditioned medium (10×) and
Wnt3a-conditioned medium (2×), both produced in-house. Culture
medium (IOM, 250 μl) supplemented with Y-27632 (Sigma-Aldrich,
10 μM) was added to each well, and plates were incubated at 37 °C.
The culture medium was changed every second day and organoids
passaged every 7 days. To attain cell differentiation, organoids were
cultured in differentiation medium from which R-spondin 1, Wnt3a,
SB201290, and nicotinamide were omitted. For single-cell re-plating
experiments, intestinal organoids were cultured for 4 days and treat-
ed with TNF (10 ng/ml), with or without supplementation of PGE2
(1 μM), or treated with PGE2 alone for 48 h. Organoids cultured
under these conditions were digested into single cells on day 7 in ac-
cordance with a well-established procedure [27]. Single cells (1500Fig. 1. The COX-2–PGE2 pathway correlates with response to TNF inhibitor in primary monocy
gene expression analysis of COX-2 in responders (Rs) (n= 10) and primary non-responders (P
intestinal biopsies from Rs, PNRs (before and after TNF inhibitor treatment), healthy control su
Scale bar, 200 μm. Magniﬁcation, 40×. (c, d) Scoring of COX-2 abundance based on the IHC sta
(before and after TNF inhibitors treatment), and healthy control subjects. Rs, n = 10; PNRs, n
mass spectrometry (GC–MS) analysis. (f) Protein levels of PGE2 were quantiﬁed by GC–MS an
control subjects, n = 6. (g) Chromatograms of PGE2 quantiﬁcations in the culture medium
responder, with or without TNF stimulation, are depicted. (a, e, f, g) Primary monocytes were
PNRs following shift to a second-line therapy, e.g., vedolizumab. (b, c, d) Colonic biopsies were
(a, c, d, f) Data are shown as medians with interquartile ranges. The Kruskal-Walls test were us
difference.cells) were cultured in IOM for 7 days, and the number of organoids
was counted under a microscope on day 7. PGE2 was purchased from
Cayman Chemical (Ann Arbor, MI, USA). Celecoxib (PZ0008) was
bought from Sigma-Aldrich, and the organoids were treated with
celecoxib (3 μM) for 48 h.
2.4. Mass Spectrometry
Primarymonocytes frompatientswere incubated overnight, and the
culturemediumwas subsequently replacedwith serum-free RPMI 1640
basalmedium. Cells were then treatedwith 10 ng/ml of TNF for 8 h. The
medium was subsequently harvested and centrifuged at 13,000 ×g for
5 min at 4 °C. To quantify eicosanoids in themedium, 100 μl of medium
was analyzed by gas chromatography–mass spectrometry (GC–MS
analysis).
2.5. RNA Extraction, cDNA Synthesis, and qPCR
RNA was puriﬁed from intestinal organoids and monocytes using
NucleoSpin columns (Macherey-Nagel, Düren, Germany). RNA (200
ng)was reverse transcribed into cDNA (SuperScript II reverse transcrip-
tase, Invitrogen) followed by SYBR green (Roche, Basel, Switzerland)
qPCR with β-actin as the housekeeping gene. All primer sequences are
listed in the Supplemental Table S2.
3. RNA-seq Analysis
Intestinal organoids were cultured for 4 days and treated with TNF
(10 ng/ml) with or without PGE2 (1 μM), or treated with PGE2 alone
for 48 h. RNA was isolated (n=3/group), and quality was assessed by
Nanodrop (OD 260/280 ≥ 2.0 and OD 260/230 ≥ 2.0) and Agilent
Bioanalyzer (RIN value ≥ 6.8). RNA-seq was done using 150-bp end
reads at Novogene, Ltd. Data were deposited at GEO data set GSE
116936. Data normalization, statistical analysis, and hierarchical clus-
tering were performed using Qlucore software (Qlucore, Lund,
Sweden). Pathway and GO term analyses were performed using the
Gene Ontology website (www.geneontology.org/).
4. Expression analyses in Independent Patient Cohorts
We analyzed ANXA1 expression using transcriptomic data from an
independent patient cohort. Intestinal biopsies were obtained form an
independent patient cohort at Herlev Hospital consisting of healthy
control subjects and UC patients with varying disease activity based
on the Mayo score [23]. Two neighboring biopsies from inﬂamed sig-
moid colon were obtained from each patient within a 5 cm radius,
fromwhich RNAwas obtained and analyzed bymicroarray as previous-
ly described [28]. In addition, we analyzed ANXA1 expression from
Affymetrixmicroarray data downloaded from theGene Expression Om-
nibus website (www.ncbi.nlm.nih.gov/geo/) and extracted data from
the GSE14580 study [29]. The study consists of microarray expression
data from intestinal biopsies from healthy control subjects, from Rs
and PNRs before and after TNF inhibitor treatment in patients with
UC. Data were generated using the Human Genome U133 Plus 2.0tes. (a) Primary human monocytes were treated with TNF (10 ng/ml) for 8 h, followed by
NRs) (n= 10). (b) Representative images of COX-2 immunohistochemistry (IHC) stains of
bjects, and isotype control, counterstained by hematoxylin. Nuclei (blue), COX-2 (brown).
ins performed in lamina propria cells and epithelium of intestinal biopsies from Rs, PNRs
= 10, and control subjects, n = 10. (e) The procedure applied for gas chromatography–
alysis in the culture medium of primary human monocytes. Rs, n = 7; PNRs, n = 6; and
of primary monocytes. Representative images of one responder and one primary non-
isolated from patients during maintenance therapy with a TNF inhibitor (Rs) or in case of
obtained from the patients before and after 14weeks of TNF inhibitor induction therapy.
ed to compare the data. *P b 0.05; **P b 0.01; ***P b 0.001; ns= no statistically signiﬁcant
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(RMA), as described in the above-mentioned study entry.4.1. Immunohistochemistry and Immunoﬂuorescence
Colonic biopsies from the sigmoid part were obtained endoscopical-
ly from the patients before and after TNF inhibitor treatment. IHC for
detection of COX-2 and MUC2 was performed on paraformaldehyde-
ﬁxed tissue and intestinal organoids. Sections were mounted on
adhesive slides (Superfrost Plus, Menzel-Glaser, Braunschweig,
Germany) and kept at 4 °C until staining on a DAKO autostainer
(DAKO, Glostrup, Denmark). COX-2 (SP21) monoclonal antibody was
purchased from Cell Marque (Rocklin, CA, USA). MUC2 (CCP58) anti-
body was purchased from DAKO. For immunoﬂuorescent detection of
MUC2 in intestinal organoids, deparafﬁnized slides were pretreated
with citrate buffer (pH 6) in a DAKO antigen retrieval machine and
then blocked with blocking buffer (3% BSA+ 0.2% Triton-100) for 1 h
at ambient temperature. Slides were incubated overnight at 4 °C with
primary anti-MUC2 antibody diluted 1:200 in blocking buffer. Stained
cellswerewashedwith PBS (3 times, 10min apart), followedby incuba-
tion with a secondary antibody (Goat anti-mouse-Alexa 488, Thermo
Fisher) diluted 1:200 in blocking buffer for 1 h. DAPI (Thermo Fisher)
was incubated for 5 min (0.1 mg/ml, diluted in PBS). After incubation,
slides were washed with PBS (3 times, 10 min apart) and mounted
using ProLong Gold Antifade Mountant (P10144, Thermo Fisher). All
images were obtained with a Leica ﬂuorescence microscope
(Manalapan, NJ, USA). For periodic acid–Schiff (PAS) staining,
paraformaldehyde-ﬁxed intestinal organoids were mounted on adhe-
sive slides, and PAS staining was carried out as described previously
[30]. Mature goblet cells were quantiﬁed by counting the number of
PAS+ goblet cells. Twenty-one microscopic images from PAS staining
were counted for each condition. The percentage of goblet cells was
deﬁned as the number of PAS+ goblet cells compared with the total
number of epithelial cells in each image.5. Evaluation of COX-2 IHC Staining
COX-2 IHC scoring was conducted by the staff pathologist, who was
blinded to all sample IDs. For each slide, the staining in lamina propria
and epithelium was scored separately. The percentage of positive cells
was scored as 0 (negative, no positive cells), 1 (b25%), 2 (25–50%), 3
(51–75%), and 4 (N75%). Staining intensity was graded as 0 (negative),
1 (weak), 2 (moderate), and 3 (strong). The degree of immunoreactivity
was calculated as the sum of the intensity score and the fraction of pos-
itive cells.5.1. Statistical Analysis
Data are presented using nonparametric statistics (i.e., medianswith
interquartile ranges). Comparisons between groups were completed
using theMann-Whitney U test. Multiple comparisons were performed
using the Kruskal-Walls test: *P b 0.05; **P b 0.01; ***P b 0.001; ****P b
0.0001; ns = no statistical signiﬁcant difference.Fig. 2. Transcriptomic proﬁling of organoids stimulated with TNF and PGE2. (a) Organoids cultu
Transcript levels from RNA sequencingwere converted into z-scores and represented as a heatm
b 0.01) between the 4 groups (n= 3 samples for each group). Rows represent samples wherea
expression levels based on z-score transformation. (b-c) The stimulated conditions were com
stimulation with TNF (1946 transcripts), PGE2 (1295 transcripts) and TNF + PGE2 (2926 tr
divided into up- and down-regulated genes and presented as Venn diagrams. (d) The gene o
up-regulated and down-regulated genes. The GO biological processes were organized by P-Valu
of selected genes. These are markers for inﬂammatory cytokines (TNF, IL8, IL-1beta, and CCL2
(MUC2, MUC5B, MUC5AC, CAII, FABP1, ACE2, and MAOA) in the 4 different conditions. Red an
normalization.6. Results
6.1. Comparison of COX-2 Expression and PGE2 Secretion between
Responders and Primary Non-Responders
Given that monocytes are important drivers of intestinal inﬂamma-
tion [9,31], we assessed the response of primary monocytes isolated
from Rs and PNRs to TNF stimulation. TNF caused a prominent tran-
scriptional induction of typical UC-associated cytokines (TNF, IL-1β, IL-
8, and IL-6), which was comparable between Rs and PNRs (Fig. S1).
TNF stimulation of primary monocytes from Rs was, however, associat-
ed with a twofold induction of COX-2 (PTGS2) expression (P b0 .01),
while no such induction was observed in monocytes from PNRs
(Fig. 1a). Importantly, the basal expression level of COX-2 in
unstimulated monocytes from PNRs was similar to the level observed
in TNF-stimulated monocytes from Rs (Fig. 1a). Monocytes from PNRs
therefore appeared to be maintained in an “inﬂammatory” state with
respect to COX-2 expression. In intestinal colonic biopsies from Rs and
PNRs (both before and after TNF inhibitor treatment) and from healthy
control subjects, COX-2 was detected in both epithelial cells and cells of
the lamina propria. In the epithelial cells, the expression of COX-2
showed no signiﬁcant changes under different conditions (Fig. 1d).
Interestingly, COX-2 expression in the lamina propria correlated with
ongoing and unresolved inﬂammation in PNRs following TNF inhibitor
treatment (Fig. 1b, c, Fig. S2a, b). Thus, in vitro, TNF stimulation led to
the induction of COX-2 in Rs, and there was a higher expression level
of COX-2 in monocytes from PNRs in the absence of exogenous TNF. In
vivo, anti-TNF treatment can resolve the inﬂammation and reduce
COX-2’s expression in the lamina propria of Rs but not in PNRs.
To determine the functional consequences of enhanced basal COX-2
expression in monocytes from PNRs, prostanoid levels were measured
in culture medium by mass spectrometry (Fig. 1e). Levels of PGE2,
PGF2α, and TxB2 (the stable metabolite of TxA2) were quantiﬁable,
whereas PGI2 and PGD2 were undetectable (Fig. 1f, g and Fig. S2c, d).
Consistent with the TNF-mediated induction of COX-2 expression in
monocytes derived from Rs (Fig. 1a), the level of PGE2 was elevated fol-
lowing TNF stimulation of monocytes from Rs but not in monocytes
from PNRs (Fig. 1f, g). The basal PGE2 levelswere again trending toward
higher levels in PNRs compared with Rs (P= 0.06). No differences in
levels of PGF2α or TxB2 between Rs or PNRs before or after TNF stimula-
tionwas detected (Fig. S2c, d). Accordingly, PGE2 productionwas direct-
ly affected by the abnormal regulation of COX-2 in PNRs. Of notice, no
correlation between patients' baseline Mayo score and the basal level
of COX2 expression/PGE2 production was detected (Supplemental
Table S3 and Table S4).
6.2. Transcriptional Proﬁling of Intestinal Organoids Stimulated with TNF
and PGE2
To address the effect of inﬂammatory stimulation on intestinal epi-
thelial cells, we performed expression analysis by RNA-seq on human
colonic epithelial organoids treated with TNF and/or PGE2. The analysis
revealed 4905 differentially expressed transcripts upon stimulation
with TNF, PGE2 or both with each culture condition exhibiting unique
sets of up and down regulated transcripts (P b 0.01; Fig. 2a). The 1946,
1295 and 2926 transcripts speciﬁcally deregulated by TNF, PGE2red in IOMwere treated for 48 h with TNF (10 ng/ml), PGE2 (1 μM) or their combination.
ap with hierarchical clustering of all signiﬁcantly different expressed transcripts (4905; P
s columns represent genes. Red and blue indicates transcripts with increased or decreased
pared to control (fold-change ≥2 and P b 0.01), and the deregulated transcripts following
anscripts) were identiﬁed. The deregulated genes of the three stimulated groups were
ntology (GO) biological process term analysis which show the pathways associated with
e and False Discovery Rate (FDR) b 0.05. (e) Heatmap presenting the transcription proﬁle
), intestinal stem cells (LGR5, PTK7, LRIG1, ASCL2, OLFM4, and SMOC2) and differentiation
d blue indicates transcripts with increased or decreased expression based on z-scores
503Y. Li et al. / EBioMedicine 36 (2018) 497–507
504 Y. Li et al. / EBioMedicine 36 (2018) 497–507and the combination when compared to controls (fold change ≥2,
P b 0.01), were divided into up- and down-regulated genes exhibiting
both unique and overlapping transcriptional responses to the treat-
ments (Fig. 2b, c).
To elucidate the functional consequences of the stimulation (TNF,
PGE2, or the combination), the biological processes associated with
the differentially expressed transcripts were assessed by gene ontology
(GO) enrichment analysis (Fig. 2d) (FDR b 0.05). The analyses revealed
that uniquely up-regulated transcripts following TNF stimulation (T1
+ T2 in Fig. 2b) were enriched for biological processes related to gener-
al inﬂammation, including apoptosis, antigen presentation, IL-10 secre-
tion, chronic inﬂammatory response as well as epithelial cell migration
(Fig. 2d). The transcripts uniquely up-regulated by PGE2 (P1 + P2 in
Fig. 2b) were similarly associated with cellular apoptosis, and addition-
ally enriched in pathways associated with extracellular matrix organi-
zation, cell-cell adhesion and regulation of a branching structure
(Fig. 2d). The shared up-regulated effects between TNF and PGE2 (C1
+ C2 in Fig. 2b)were enriched for cell adhesion and inﬂammation relat-
ed antigen processing andpresentation (Fig. 2d). Theup-regulated tran-
scripts when combining TNF and PGE2 (P2+ TP1+ T2+ C2 in Fig. 2b)
were associated with inﬂammation resembling the biological functions
of TNF stimulation with an additional impact on processes related to
cell-matrix adhesion (Fig. 2d). All the down-regulated transcripts
(Fig. 2c) were mainly correlated to basic cellular processes, including
DNA replication, RNA processing, translation and cell proliferation,
with nomajor differences in the associated GO-term between the treat-
ment conditions (Fig. 2d).
The expression of inﬂammatory cytokines and marker genes for
speciﬁc cellular subsets were additionally evaluated (Fig. 2e). As ex-
pected, TNF upregulated the expression of inﬂammatory cytokines,
which could be further enhanced by the addition of PGE2. Moreover,
repression of intestinal stem cell markers by PGE2 following TNF
stimulation was observed, implying a synergistic effect of TNF and
PGE2 stimulation on both inﬂammation and stem cell maintenance.
In addition, we found that the expression of goblet cell markers
(MUC2, MUC5B, and MUC5AC) was induced by PGE2, and that
PGE2 downregulated the expression of enterocytes markers (CAII,
FABP1, ACE2, and MAOA). These data combined indicate that contin-
uous activation of the COX-2-PGE2 pathway in PNRs exacerbates the
proinﬂammatory state of intestinal epithelium induced by TNF, thus
potentially reducing the stem cell population and impairing epithe-
lial regeneration.
6.3. Effect of PGE2 on the Self-Renewal of Intestinal Epithelial Stem Cells
With the identiﬁed impact of PGE2 on the expression of markers
of stem cells and the reported beneﬁcial effect on in vitro expansion
of intestinal epithelial cells [32], we performed single-cell reseeding
experiments in order to measure the direct effect of PGE2 on the
fraction of cells with self-renewal properties. Whereas pretreatment
with TNF alone did not signiﬁcantly alter organoid-forming capacity,
the combination with PGE2 led to a signiﬁcant reduction in organoid-
forming efﬁciency when compared with control samples (P b 0.001;
Fig. 3a, b). Despite the previously reported role of PGE2 as supporting
long-term maintenance of intestinal epithelial cells [32], treatment
with PGE2 alone reduced the organoid-forming efﬁciency when com-
pared with unstimulated cells (Fig. 3a, b). In line with the reducedFig. 3. PGE2 and TNF affect themaintenance of intestinal stem cells. (a) Organoids cultured in IO
re-plating was performed on day 7, and cells were cultured in IOM medium for an additional 1
intestinal organoids on day 7 before reseeding of single cells, described in (a). Scale bar, 100
and PGE2 (1 μM) for 48 h, followed by gene expression analysis of LGR5, KI67, and ANXA1. (f) G
UC (mild: n= 11; moderate: n= 24; and severe: n= 10), UC in remission (n= 21), and hea
Kruskal-Walls test was used to compare the data. (g, h) Gene expression of COX-2/ANXA1 fro
(n= 8), and PNRs (n= 16) including values before and after treatment with inﬂiximab. Data
biological replicates with interquartile ranges and are from one of three independent experim
was used to compare the data. *P b 0.05; **P b 0.01; ***P b 0.001; ****P b 0.0001; ns= no statisself-renewal capacity and the observed reduction in the expression
of stem cell marker genes in the RNAseq experiments, organoids
treated with TNF and PGE2 also expressed lower levels of the adult
stem cell marker LGR5 and the proliferation marker KI67 when com-
pared with unstimulated control samples (Fig. 3c, d, Fig. S3). These
ﬁndings show that cells in a TNF and PGE2 driven proinﬂammatory
state have a compromised stem cell function. Of note, Annexin A1
(ANXA1), which is expressed speciﬁcally by the repairing epithelium
following tissue damage [33], was upregulated on PGE2 stimulation
suggesting that this is associated with a change in cellular identity
(Fig. 3e). Analysis of microarray expression proﬁles obtained from in-
testinal biopsies of patients with active UC and healthy control sub-
jects demonstrated a signiﬁcant correlation between ANXA1
expression and disease severity (Fig. 3f). Additionally, previously
published expression data (GSE14580) of intestinal biopsies from pa-
tients with UC [29], including Rs and PNRs to TNF inhibitors, showed
that the expression of both COX-2 and ANXA1 indeed are elevated in
PNRs when compared with Rs and healthy control subjects (Fig. 3g,
h). These observations indicate that a higher expression of COX-2
and ANXA1 accompanies a continued inﬂammatory state in PNRs fol-
lowing therapy with TNF inhibitors.6.4. Effect of PGE2 on the Differentiation of Intestinal Epithelial Stem Cells
Appropriate differentiation of the intestinal epithelium is crucial fol-
lowing inﬂammation and wound formation for reestablishing a func-
tional epithelial barrier [34]. We therefore explored the effects of PGE2
on intestinal epithelial differentiation by altering medium composition
from conditions supporting stem cell self-renewal and expansion
(intestinal organoid medium [IOM]) to differentiation (differentiation
medium [dm]) (Fig. S4). Under IOM conditions, stimulation with PGE2
induced a slight increase in the expression of several mucin-associated
genes normally expressed by goblet cells (MUCIN2 [MUC2] [twofold,
P b 0.01], MUC5B [eightfold, P b 0.01], MUC5AC [11-fold, P b 0.01])
(Fig. 4a), conﬁrming the effects on goblet cell differentiation previously
observed (Fig. 2e). PGE2 stimulation did not affect the expression of car-
bonic anhydrase II (CAII) or chromogranin A (CHGA), which aremarkers
for enterocytes and enteroendocrine cells, respectively (Fig. 4a). Follow-
ing culture of the cells under differentiation conditions, which mimic
the egress of stem cells from the stem cell compartment, we found
that PGE2 dramatically induced the expression of markers for goblet
cells (P b 0.01; Fig. 4a), where expression of CHGA was suppressed
(Fig. 4a, Supplemental Table S5). At the protein level, MUC2 (the dom-
inant gel-forming mucin produced by goblet cells) was markedly in-
duced by PGE2, as determined by both ﬂuorescent and chromogenic
IHC staining of organoid cultures (Fig. 4b, c). Moreover, this was associ-
atedwith a concordant increase in the number of PAS+ cells, which rep-
resents a hallmark of goblet cell differentiation (Fig. 4d). Using the
speciﬁc COX-2 inhibitor celecoxib, the induction of MUC2 expression
by TNF was inhibited, and the inhibitory effect of celecoxib could be
bypassed by addition of exogenous PGE2 (Fig. 4e).
In this way, our data suggest that the effect of PGE2 on intestinal ep-
ithelium depends on the presence of concomitant inﬂammation. During
intestinal homeostasis, PGE2 promotes goblet cell differentiation,
whereas it drives the epithelial cells into a state with impaired stem
cell population during inﬂammation (Fig. 4f).Mwere treated for 48 hwith a combination of TNF (10 ng/ml) and PGE2 (1 μM). Single-cell
0 days. The organoid-forming capacity was assessed on day 7. (b) Microscopic images of
μm. (c–e) Organoids cultured in IOM were treated with combinations of TNF (10 ng/ml)
ene expression of ANXA1 from microarray data on colonic tissues of patients with active
lthy control subjects (n= 20). Data are shown as medians with interquartile ranges. The
m previous microarray data on colonic tissues from healthy control subjects (n= 6), Rs
were derived from GEO data set GSE14580. (a, c-e) Data are shown as the median of six
ents in which the organoids were from three different patients. The Kruskal-Walls test
tically signiﬁcant difference.
Fig. 4. PGE2 promotes the expression of mucins. (a) Organoids were cultured in IOM or dm, with or without the addition of PGE2 for 48 h. PGE2 treatment (1 μM). Gene expression of
mucins (MUC2, MUC5B, and MUC5AC, which are markers for goblet cells), CAII (enterocyte marker), and CHGA (enteroendocrine marker) were measured by qPCR. The expression of
CHGA could not be detected in IOM culture conditions. N.D. = not detected. (b–d) Organoids cultured in dm were treated with or without PGE2 for 48 h, and then
immunoﬂuorescence (b) and IHC (c) were performed for detection of MUC2. DAPI (blue), MUC2 (green). Periodic acid–Schiff (PAS) staining (d) was conducted, and mature goblet
cells were quantiﬁed by counting of PAS+ goblet cells. (e) Organoids cultured in dm were treated with combinations of TNF (10 ng/ml), the COX-2 inhibitor celecoxib (3 μM), and
PGE2 (1 μM) for 48 h. Gene expression ofMUC2 was assessed by qPCR. (f) Schematic depiction of the correlation between COX-2–PGE2 pathway and the responsiveness to treatment
with TNF inhibitors. (a, e) Data are shown as the median of six biological replicates with interquartile ranges and are from one of three independent experiments. The Mann-Whitney
U test was used to compare the data. (d) Data are shown as the median with interquartile ranges and are from one of two independent experiments. Mann-Whitney U tests were used
to compare the data. *P b 0.05; **P b 0.01; ***P b 0.001; ns= no statistically signiﬁcant difference.
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Identiﬁcation of mechanisms that inﬂuence the responsiveness to
TNF inhibitorsmight enable clinicians to predict the response and to po-
tentially devise new and more rational and tailored treatment strate-
gies. This is consequently of major clinical importance for the
management of patients with IBD. In this study, we for the ﬁrst time
show thatmonocytes fromRs display increased expression of COX-2 fol-
lowing TNF stimulation, whereas this is not the case for PNRs due to a
higher basal expression level of COX-2. The continuously augmented
inﬂammation-independent expression of COX-2 and secretion of PGE2
bymonocytes fromPNRs, indicate thatmonocytes fromPNRs fail to reg-
ulate PGE2 synthesis, which potentially leads to exacerbation of the in-
ﬂammatory state in the intestinal mucosa. This notion is supported by
the observation that the dominant metabolite induced by COX-2,
PGE2, in this experimental setup enhances the proinﬂammatory effect
of TNF in intestinal epithelial cells.
The PNRs in this study were initially treated with a TNF inhibitor,
inﬂiximab, but were after the induction regimen switched out of class
to different therapeutic options due to the lack of response. These ther-
apeutic options include anti-integrins such as vedolizumab, along with
e.g., thiopurines like azathioprine, glucocorticoids or 5-ASA. COX-2 ex-
pression has been proposed to be targeted by glucocorticoids, which
was administered to one out of ten PNRs in this study [35]. Furthermore,
seven out of ten PNRs received vedolizumab therapy at blood sampling.
However, it remains unknownwhether vedolizumab affects the level of
COX-2 in monocytes. Moreover, the use of azathioprine and 5-ASA in
the study cohort was comparable between Rs and PNRs (Supplemental
Table S1). These two therapies might also inﬂuence the expression of
COX-2 as previously reported in DSS-inducedmurine colitis and in can-
cer cell lines [36,37]. Although the regulation of COX-2 could be affected
by the therapies, the patient cohorts analyzed in this study were largely
comparable except for the biologics with scarcely reported impact on
COX-2 activity and levels. Thus, our results therefore reveal that it
might be of importance to further validate the expression of COX-2
prior to treatment with TNF inhibitors in the future.
Induction of COX-2 has been shown to correlatewith initiation of the
mucosal healing process following intestinal wound formation
[16,17,38], and the concentration of PGE2 is elevated in colonic tissue
of patients with ﬂaring UC [39]. In the initial phases of wound healing,
murine studies have revealed that PGE2 induces a speciﬁc cellular
state characterized by the expression of genes associated with WAE
cells [19]. It is evident that induction of PGE2 and the existence of
WAE cells is transient, and once wound closure has been achieved,
PGE2 levels return to normal [40]. Epithelial re-differentiation will sub-
sequently direct completion of tissue remodeling and restore of epithe-
lial integrity. Taken together, these results imply that PGE2 plays a key
role in the initial phases of wound re-epithelialization.We demonstrate
that ongoing COX-2 activity precludes later phases of regeneration and
ultimately mucosal healing. The expression analysis supports this no-
tion, as a GO analysis reveals that biological processes regulated by
PGE2 are functionally associated with cell-cell adhesion and cellular ap-
optosis, and able to exacerbate the proinﬂammatory state of intestinal
epithelial cells following stimulation with TNF.
In terms of cellular differentiation, PGE2 induced the expression of
markers for goblet cells both during homeostasis, but also during TNF in-
duced inﬂammation. The importance of PGE2 for goblet cell differentia-
tion during steady-state homeostasis is reinforced by the clinical
observations indicating a central role of COX-2 for themaintenance of re-
mission in UC [16,17]. Further, we observed that PGE2 inhibited the self-
renewal of intestinal stem cells during TNF treatment. In fact, the combi-
nation of PGE2 and TNF represses normal stem cell functions and drives
cells into a different inﬂammatory state that is characterized by expres-
sion of TNF, IL-8, IL-1β, and AXNA1. Hence our ﬁndings indicate that in
PNRs, the sustained induction of PGE2 continuously promotes cell states
associated with the inﬂammatory epithelium, thereby compromisingtissue remodeling and regeneration. Epithelial reconstitution is a pivotal
treatment goal in UC, a process in which both epithelial cells and mono-
cytes/macrophages are involved [9,31]. Unlike Rs, where monocytes
upon treatment with TNF inhibitors decrease COX-2 expression and
thus reduce PGE2 secretion, the epithelial cells of PNRs are kept in an in-
ﬂammatory state, which in turn, is incompatible with reestablishment of
tissue homeostasis. Thus, we propose a novel pathophysiologic mecha-
nism based on PGE2 and TNF in the epithelial injury response associated
with ﬂaring UC, and we provide a plausible explanation as to why PNRs
do not beneﬁt from treatment with TNF inhibitors. We also describe for
the ﬁrst time an important and previously overlooked function of PGE2
in regulating the differentiation of human intestinal epithelial cells dur-
ing homeostatic conditions by promoting barrier reinforcement via gob-
let cell differentiation and mucin production.
Although this study was not prospective in its design, it is tempting
to speculate that the basal expression of COX-2 in monocytes may be
used to identify Rs and PNRs before initiation of TNF inhibitors in future
clinical settings. A better understanding of PGE2 signaling and its impact
on the different phases of tissue homeostasis and regenerationwill help
to shed light on the underlying mechanisms of the COX-2–PGE2 axis,
and whether this might be a druggable pathway to modulate TNF re-
sponsiveness in the future.
Supplementary data to this article can be found online at https://doi.
org/10.1016/j.ebiom.2018.08.040.
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